Desteklenen Projeler
-
2023 - Devam Ediyor Kronik Lenfositik Lösemi Hücrelerinde Dioscinin NLRP3 İnflamazomun İfadelenmesine ve Apoptoza Etkileri
Yükseköğretim Kurumları Destekli Proje
GÖKÇEN S. (Yürütücü), KAYHAN H., YAĞCI A. M., ÖZKURT Z. N., YEGİN Z. A.
-
2023 - 2030 A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023 - 2029 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody in Previously Untreated Participants with Follicular Lymphoma (FL) (OLYMPIA-2))
-
2023 - 2029 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Folliculr Lymphoma (FL) (OLYMPIA-1)
-
2023 - 2029 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
-
2023 - 2029 A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-
2022 - 2028 A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2021 - 2027 A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
-
2022 - 2026 MOR208C310A Phase 3, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R- CHOP versus R-CHOP in high-intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma
-
2021 - 2026 A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
-
2020 - 2025 A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versus in Combination with Acalabrutinib in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma / D8227C00001 / ACE-LY-312
-
2019 - 2024 A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemo immunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
-
2016 - 2024 A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
-
2014 - 2024 A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma